 Thursday, July 14th, 2011 This is a Wealth Wire breaking news alert... The doctor behind a $30 million biotech company has just told the world he's discovered a way to “print” replacement tissues and organs. CNN showed a clip last weekend in which the same doctor explained the device is already “being explored for organs such as the kidney and structured tissue such as the ear.” This is just the latest achievement on this young company's impressive résumé. Featured on 60 Minutes last year, this doctor and his company have proven they can grow bladders and tracheas with a similar technique. What's more, they believe this type of medicine will reduce health care costs by $250 billion annually because the results it delivers cures diseases instead of treating them. The U.S. Department of Health and Human Services has already declared this the “next evolution” of medicine. The military and the FDA are excited as well, both offering incentives to further the technology along. It will drastically change our notion of health. And as this free report shows, it could have even more profound effects on wealth. Good Investing, Wealth Wire Wealth Wire, Copyright © 2011, Angel Publishing LLC, P.O. Box 84905, Phoenix, AZ 85071. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Wealth Wire does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this newsletter. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription. |
No comments:
Post a Comment